Glasdegib maleate

{
  "id": "MLC-T-ONC-003559",
  "term": "Glasdegib maleate",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used with low-dose cytarabine to treat acute myeloid leukemia that is newly diagnosed. It is used in patients who are 75 years and older or in patients who cannot be treated with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Glasdegib maleate blocks a type of protein involved in cell growth and repair and may block the growth of cancer cells. It is a type of hedgehog signaling pathway antagonist. Also called Daurismo.",
    "The maleate salt form of glasdegib, an orally bioavailable small-molecule, smoothened (SMO) receptor inhibitor, with potential antineoplastic activity. Upon oral administration, glasdegib targets, binds to and inhibits the activity of SMO. This inhibits the activity of the Hedgehog (Hh) signaling pathway and inhibits the growth of tumor cells in which this pathway is aberrantly activated. SMO, a transmembrane protein, is involved in Hh signal transduction. The Hh signaling pathway plays an important role in cellular growth, differentiation, repair, and cancer stem cell (CSC) survival. Constitutive activation of Hh pathway signaling has been observed in various types of malignancies and is associated with uncontrolled cellular proliferation in a variety of cancers."
  ],
  "synonyms": [
    "Daurismo"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/glasdegib-maleate/"
}